A non-transformed human fibroblast strain, GM11, established from the skin of a therapeutically aborted fetus, has been reported to exhibit the Mer" phenotype, i.e. inability to support the growth of adenovirus 5 damaged with l-methyl-3-nitro-l-nitrosoguanidme. In the present study we determined (i) loss of colony-forming ability and frequency of mutants resistant to 6-thioguanine (6TG) on exposure to the S, v l alkylating agent methylnitrosourea (MNU) and ( 2 mM) ; the induced mutation frequency in these cells (passage 16-20) was equal to 220 x 10~6/mM MNU, a yield some 5-fold greater than that reported by others for non-fetal human fibroblasts. GM11 cells proved to be only ~ 1.5 times more mutable by MNU than GM10 cells at late passage, and the susceptibility of the former strain to MNU-induced mutations did not change significantly as a function of culture age (i.e. 316 x 10~6 and 326 x 10" 6 mutants/mM MNU at passages 4 and 16-20 respectively). The GM10 strain contained -75 000 MGMT molecules/cell at all passages (4-20) examined, whereas the GM11 strain harbored deficient amounts of the protein (~22 500 molecules/cell) at the lowest passage available (4), and this residual activity decreased precipitously to undetectable amounts by passage 16. Together, these data demonstrate that in the two human fetal strains examined the constitutive level of cellular MGMT activity correlates much better with resistance to reproductive inactivation than with mutagenesis by MNU, implying that inefficient repair of OSieG lesions impacts more severely on cell lethality than on mutation induction in at least some biological systems.
Introduction
The Stfl-type alkylating agents methylnitrosourea (MNU*) and l-methyl-3-nitro-l-nitrosoguanidine (MNNG), two potent mutagenic and carcinogenic chemicals, react with the oxygen and nitrogen atoms of the heterocyclic bases to form assorted adducts in cellular DNA, notably AG-methyladenine, A7-methylguanine and O^-methylguanine (OVieG). By contrast, the S^-type alkylating agent methylmethanesulfonate (MMS), a weak mutagen, produces primarily N-alkylated bases, thus incriminating O-alkylated bases in general and O 6 meG residues in particular as deleterious DNA lesions induced by N-nitroso compounds (reviewed in refs 1-3). In keeping with this prediction, O meG adducts are known to mispair with thymines during DNA replication, and thereby produce transition mutations (3). It is not surprising, therefore, that bacterial and mammalian cells alike are endowed witfi a DNA repair protein, CPmethylguanine-DNA methyltransferase (MGMT), responsible for ensuring rapid elimination of 0 6 meG lesions before the DNA replication machinery can encounter them. In a peculiar reaction, the MGMT protein mediates the direct stoichiometric transfer of me offending alkyl group from die O 6 position of guanine in DNA to one of its own cysteine residues, the acceptance of which inactivates the protein molecule. This suicidal transmethylation reaction is specific for O 6 meG adducts in human cells (4, 5) and additionally for (7*-methylthyrnine and methylphosphotriester lesions in the bacterium Escherichia coli (3) . In contrast, the nitrogen-alkylated bases, exemplified by A/3-methylpurines, are released from genomic DNA as free entities by the action of lesion-specific DNA glycosylases, whereupon the resulting apurinic sites are operated on by a conventional excision repair mechanism sequentially entailing strand incision/AP site excision/repair synthesis/strand ligation reactions (1) (2) (3) .
Sophisticated genetic and biochemical analyses of mutant strains and cell-free systems readily available in E.coli have provided detailed insight into the innermost workings of enzymatic repair systems operative on DNA alkylation damage in lower organisms (1) (2) (3) . These molecular studies have also revealed the contribution of individual reaction products towards the adverse biological effects of a given alkylating agent, identifying O meG as the DNA adduct primarily responsible for die marked mutagenicity of N-nitroso compounds and AG-metiiylpurines as potentially lethal lesions (1) (2) (3) 6, 7) . In mammalian systems, however, the precise role of O 6 meG adducts in die different biological changes caused by alkylating agents remains contentious. The findings of Day et al. (8, 9 ) that a group of tumor and simian virus 40 (SV40)-transformed human cell lines (defined Mer") lacked the ability to support the growth of MNNGtreated adenovirus and also failed to repair O 6 meG from genomic DNA suggested a critical role for diis lesion in alkylation-induced cytotoxicity. While in certain subsequent studies die persistence of 0 6 meG in DNA has been found to correlate wim cytotoxicity (10, 11) , sister chromatid exchanges (12 -14) , mutagenesis (15, 16) and carcinogenesis (17) by MNU or MNNG, diere are also reports identifying memylation products other than O 6 meG as the primary contributor to the various deleterious effects of these agents (18) (19) (20) (21) (22) (23) (24) .
In the course of examining loss of colony-forming ability in a panel of human fibroblast strains in response to MNU treatment, we have demonstrated that a non-transformed fibroblast strain, designated GM11, which was derived from the skin of a human fetus, displayed enhanced MNU sensitivity and deficient levels of constitutive MGMT activity (25). Domoradzki et al. (15) subsequently reported these fetal cells to be markedly more susceptible than non-fetal, MGMT-proficient (Mer + ) human fibroblasts to both cell killing and mutagenesis induced by MNNG. Given that the frequency of mutations induced by a particular genotoxic agent has been demonstrated to vary substantially among different types of human cell cultures (26) (27) (28) ; also see Discussion), we decided to examine the cytotoxic and mutagenic effects of MNU in GM11 (Mer~) cells compared to GM10, a human fetal fibroblast strain exhibiting the Mer + phenotype (29) . We report here that levels of MGMTactivity in GM10 and GM11 cells correlate with extent of hypersensitivity to cellular inactivation but not to mutagenesis induced by MNU.
Materials and methods

Cells and their cultivation
The non-transformed cell strains GM10 and GM11 (NIGMS Human Genetic Mutant Cell Repository, Camden, NJ) were derived from me skin of two apparentiy normal human fetuses (10 and 8 weeks old respectively) resulting from therapeutic abortions. The cells were free of Mycoplasma contamination as significH by the assay of Schneider et aL (30) . Cells were cultivated at 37°C in hypoxanthinefree Ham's F10 medium supplemented with 15% (v/v) fetal bovine serum, 1 mM glutamine, 100 units penicillin G/ml and 100 /ig streptomycin sulfate/ml in a humidified atmosphere of 5% CO? in air. The buffering capacity of the medium was enhanced by increasing the concentration of NaHCO^ to 2.2 g/1 (31) . All cell culture supplies were purchased from GIBCO Laboratories (Grand Island, NY).
Chemicals
A 200-mM stock solution of MNU was prepared by dissolving the compound in absolute ethanol. MMS was diluted in ethanol at a stock concentration of 100 mM. 6-Thioguanine (6TG) was dissolved in 1 % NaHCO 3 solution, filter sterilized and then diluted 100 times in culture medium to give a final concentration of 40 /iM. Stock solutions of all three chemicals were prepared fresh before each experiment.The chemicals were purchased from Sigma Chemical Co. Ltd (St Louis, MO).
Survival experiments
Cell survival was determined by the loss of colony-forming ability using the 'replating' and in situ procedures. For the former assay, which was carried out in conjunction with mutation induction experiments, cultures were inoculated at -10 4 cells/cm 2 , incubated overnight, and treated for 1 h with MNU, after which they were trypsinized and plated at cloning densities (100-10 000 cells/dish) in 100 mm dishes that had been pre-seeded with 7-ray-inactivated (50 Gy) feeder cells of the same strain (giving a total of 5 x 10 4 cells/plate). For the in situ assay, the exponentially growing cultures were seeded at known densities (100-100 000 cells/dish) and incubated for 16-20 h prior to treatment with either MNU or MMS; feeder cells were then added to each dish, as described above. All cultures were incubated with weekly media changes (13 ml), and after 14 days, clones were fixed, stained and counted. Cell survival was quantitated by comparing the cloning efficiency of MNU-treated cultures with that of the sham-treated controls.
Mutagenesis experiments
Induction of mutation to 6TG resistance was assayed as follows. Exponentially growing cultures were plated at -2 x 10*/150 mm dish, incubated overnight and then treated (or sham-treated) with MNU. Sufficient numbers of plates were used for each treatment schedule to obtain -5 X 10* surviving cells on the day of mutant selection. The treated and control (sham-treated) populations were maintained in exponential growth for 10-17 days to allow the expression of induced mutations. At the time of mutant selection, cells from corresponding treatments were pooled, and 2.5 x 10* cells were seeded in 100 mm dishes (5 x 10 4 cells/dish) in growth medium containing 40 /iM 6TG. The cloning efficiency at the time of selection was determined by seeding 100-500 cells (taken from the same cell suspension used for mutant selection prior to the addition of 6TG) per 100 mm dish that contained 5 x 10 4 7-ray-inactivated feeder cells. Cultures were refed once a week, and the clones were fixed after 2-3 weeks and stained prior to counting. Reconstruction studies (not shown) indicated that GM10 and GM11 cells responded similarly to me cytotoxic action of 6TG, and that in both strains the efficiency of recovery of 6TG-resistant clones at the cell densities used was ^95%. (The latter reconstruction experiment was carried out as described in ref. 32.) Mutation frequency was determined from the Poisson distribution using the P o method. In this approach the mean number of mutant clones per plate (m) is calculated from the equation P o = e~m, where P o is the fraction of the Petri dishes without colonies. The number of mutant clones is divided by the corresponding cloning efficiency at the time of selection to yield the mutation frequency. Correction of this value for background frequency (i.e. that observed in sham-treated cultures) gives mutation induction frequency of MNU-exposed populations.
Assay for MGMT activity
Cultures at late logarithmic phase of growth were rinsed with PBS and scraped off the dishes with a rubber policeman after which they were pelleted, resuspended at -2 x 10 7 cells/ml of buffer A [70 mM HEPES (pH 7.8), 1 mM DTT, 1 mM EDTA, 5% glycerol, 50 JJM spermidine], disrupted by sonication, and then centrifuged at 15 600 g for 60 min in an Eppendorf microcentrifuge (Canlab, Toronto). Protein concentrations in the supernatant of cell sonicates were determined by the fluorescamine procedure of Marko and co-workers (33) .
C^meC-enriched DNA was prepared as follows. Commercially obtained Micrococcus luteus DNA (high in GC content) was suspended at 5 mg/ml in 0.2 M sodium cacodylate, 1 mM EDTA (pH 7.2). Five milliliters of this DNA solution was incubated for 2 h at 37 °C with 1 mCi [methyl- 3 H]JV-nitrosourea (2 Ci/mmol). The labeled DNA was ethanol precipitated, redissolved in 0.1 M NaCl, 10 mM sodium citrate, 10 mM potassium phosphate (pH 7.4), and extensively dialyzed against the same buffer. The DNA was then sealed in thickwalled capillary tubes and heated to 80°C for 18 h to liberate most of the alkylated purines, thus enriching for (/meG (-70% of remaining label in CAneG as confirmed by substrate analysis employing HPLQ. Finally, the O 6 meG-enriched DNA substrate was extensively dialyzed against 10 mM Tris-HCl, 1 mM EDTA (pH 8.0).
Cellular MGMT activity was determined by measuring radioactivity transferred from the Cfymethyl- (34) , the reaction mixtures were incubated with 1 ml of 5% TCA for 30 mm at 80°C to hydrolyze selectively the DNA. The mixtures were then chilled to 4°C and filtered under suction on Whatman glass filters. After successive washes with 5% TCA and ethanol, the filters were dried and counted in a liquid scintillation counter. In earlier experiments specific transfer of OVieG to protein was confirmed by HPLC analysis of reaction mixtures.
Results
The effects of MNU on the colony-forming ability of GM10 and GM11 cells are compared in Figure 1 . GM10 cells showed a survival curve with a distinct shoulder up to -0.4 mM MNU. Doses required to reduce colony-forming ability to 10% (i.e. D 10 values) in these cells ranged from 1.25 to 1.55 mM when assayed at different passages. The response of GM10 cells to MNU-induced cell killing was similar to that displayed by several other normal fibroblast strains examined (data not shown); these included three human fetal strains (F7, 1381 and 1475) and skin fibroblasts from a 9 year old (GM38) and a 42 year old (GM43) clinically normal subject. GM11 cells, however, exhibited abnormal sensitivity to MNU, and there was no apparent shoulder on their survival curves. Based on the D 10 value, the degree of hypersensitivity of GM11 cells increased from ~ 2-fold at passage 4 (£> 10 ~0.6 mM) to at least an order of magnitude at passage 27 (D 10 -0.1 mM) when compared to GM10 cells of the same passage (Figure 1 ). In addition, GM11 cultures at passage 16-20 showed hypersensitivity to MMS (Figure 2 ) but they responded normally to the toxic actions of mitomycin C, far-UV (254 run) light and ''to 7-radiation (data not shown).
To compare the sensitivities of GM10 and GM11 cells to mutation induction by MNU, cultures at the earliest passage available (passage 4) were exposed to the drug and concomitantly assayed for induction of 6TG resistance and cytotoxicity; a portion of cells was grown until passage 16 or greater and then assayed. The amount of cellular MGMT activity was determined in parallel. Table I presents the results of mutation experiments obtained with GM10 cells after treatment with essentially non-toxic doses of MNU (0.05-0.3 mM). In each of four experiments (16 determinations in total), the mutation frequency in the treated cultures was much greater than the spontaneous background frequency. Moreover, in spite of the biphasic dose-dependent response for survival (Figure 1) , the induced mutation frequency in GM10 cells increased linearly (with no apparent threshold) with increasing MNU concentrations to 1.2 mM (Figure 3, top  panel) . Since the dose-response mutation curve for GM11 cells also did not appear to deviate from linearity ( Figure 3 , bottom panel), we calculated the incidence of mutations induced by each unit dose (mM) of MNU for both strains. As seen in Table II , despite the fact that GM11 cells at late passages were -10-fold hypersensitive to killing by MNU, they were only 1.5 times more sensitive than GM10 to MNU-induced 6TG resistance. More- over, in sharp contrast to that seen for cell survival (Figure 1 ; Table II), the frequency of MNU-induced mutagenesis was unchanged in GM11 cells when assayed at early and late passages ( Figure 3 ; Table n) .
Cellular sonicates of GM10 cells (passages 4-20) contained 71 000-77 000 MGMT molecules/cell (Table IT) . These values are within the range of those present within several human fetal strains including F7, 1381 and 1475 (65 000-80 000 MGMT molecules/cell). GM11 cells, on the other hand, contained reduced levels of MGMT activity, the level decreasing from 30% of normal at passage 4 to undetectable values at passage 16 (Table II) . Sonicates of GM10 and GM11 cultures possessed comparable amounts of DNA glycosylases active on A7-methylguanine and AG-methyladenine (data not shown).
Discussion
The human MGMT protein is known to remove specifically alkyl groups from the Opposition of guanine but not from any other alkylation product (4, 5) . As a result of inactivation of this protein in the reaction and its slow regeneration in MGMT-proficient cells (3, 4) , the rate of repair of O 6 meG residues in DNA is directly dependent on carcinogen dose. This is reflected by the half-life for 0 6 meG increasing from ~ 1 h following treatment with 0.1 mM MNU to ~ 24 h on exposure to 0.5 mM (35) . The dose-response curves for biological changes caused by this reaction product in MGMT-proficient cells is, therefore, expected to contain a non-effect region at low doses (due to lesion removal prior to fixation of its deleterious effects), followed by an exponential region at higher (repair-saturating) doses (4, 15) . In addition, there should exist an inverse correlation between the amount of constitutive MGMT activity and cellular sensitivity to agents that produce high levels of O 6 meG. This is precisely what is observed for induction of cell killing by MNU in the two human fetal strains examined here: GMIO (MGMTproficient) cells responded normally to MNU-induced loss of colony-forming ability, namely their survival curves exhibited a shoulder for MNU concentration is up to -0.4 mM and a D w value of ~ 1.4 mM (Figure 1 ), whereas GM11 cells showed an in vitro age-dependent decrease in MGMT activity and were also hypersensitive to MNU. In comparison with the same passage GMIO cells, the degree of enhanced sensitivity in GM11 cells increased from -2-fold at passage 4 (containing -30% residual MGMT activity) to at least an order of magnitude at late passages [containing undetectable levels (i.e. <5%) of MGMT] (Figure 1 ; Table II) . The precise mechanism underlying enhanced susceptibility of Mer~ cells to inactivation by N-nitroso compounds is still unknown, though it is becoming increasingly evident that O 6 meG residues in DNA per se are not the lesions responsible for this anomaly (see, e.g., refs. 12, 18, 19, 36) . Recent observations of Wani et al. (37) demonstrating that GMll cells are impaired in removing C^-ethylthymine and that in normal human cells the repair of this lesion is not mediated by an alkyltransferase suggests that the defect in these Mer~ cells entails more than a failure to mend Cr^meG lesions. Consistent with this notion, GM11 cells proved to be hypersensitive to MMS ( Figure  2 ). a methylating agent that produces negligible amounts of CrmeG in DNA (2, 3) . It has been postulated that the mammalian MGMT protein, in addition to repairing 0 6 meG, may regulate the expression of one or more genes responsible for removal of cytotoxic alkylation products (19, 36) , as seen in the ada system of E.coli (38) . If so, then the MGMT-deficiency in mammalian cells should have generally been associated with enhanced lethality; this is clearly not the case (see, e.g., 4, 12, 18, 19) . Alternatively, we propose that the fundamental defect in certain MGMT-deficient cell lines (including GMll) may reside in a regulatory pathway that controls multiple mechanisms, including (i) expression of the 'intact' MGMT gene and (ii) a putative process (39) that protects against inactivation by methylating agents. In support of this hypothesis, human cell lines have been identified that exhibit the Mer~ phenotype while responding normally to MNNG-induced cell killing (19, 39) . The defect in these cell lines presumably involves the MGMT gene but not the postulated tolerance mechanism (39) .
Several studies on mammalian systems have identified O 6 meG lesions in DNA as the major contributor to both cell killing and mutagenesis by methylating carcinogens (2-4,9,10,16). However, as shown in Table I , exposure of GM10 (MGMTproficient) cells to low, non-toxic doses of MNU (0.05 -0.3 mM) resulted in a high incidence of 6TG-resistant mutants indicating that, at least for MNU, the lesions which promote mutagenesis do not cause loss of colony-forming ability. Moreover, unlike the biphasic dose-response seen for survival, the relationship between mutation induction frequency and MNU dose (0.05 -1.2 mM) did not deviate from linearity in GM10 cells (Figure 3) . Finally, the MGMT-deficient (GMll) cells were only 1.5-fold hypermutable by MNU (Table H) , and there was no correlation between the amount of cellular MGMT protein and degree of sensitivity to MNU-induced 6TG resistance in these cells ( Figure 3 ; Table II ). Together, these findings suggest that in GM10 and GM11 cells, MNU products other than those repaired by MGMT (i.e. O 6 meG) are predominantly responsible for induction of mutations at the hypoxanthine-guanine phosphoribosyl transferase locus. Medcalf and Wade (40) measured the cytotoxic and mutagenic effects of MNU in non-transformed human fibroblasts. If the results obtained with NSF791 (normal) strain, presented in Table II of their paper, were plotted against corresponding concentrations of the drug, dose-response curves similar to those reported here for GM10 cells would be generated, i.e. a biphasic curve for survival with a non-effect region at low doses (<0.3 mM) and a linear mutation curve without a threshold at non-cytotoxic treatments. It should be noted, however, that the incidence of mutations induced by a given dose of MNU in GM10 cells (Table II) is ~ 5-fold greater than that reported by these workers for normal adult fibroblast strains (40) . Likewise, the induction of comparable levels of 6TG-resistant mutations (e.g. 20 mutants/10^ survivors) has been demonstrated to require a concentration of -0.2 /tM MNNG for an SV40-transformed human cell line (strain GM637; ref. 15 ), ~2 /tM for nontransformed normal human fibroblasts (strains SL68 and 2938; ref. 15) , and > 10 /iM for a tumor-derived human cell line (strain HeLa S3 Mer + ; ref. 41) . And yet all three cell cultures are MGMT-proficient. In view of these observations, care should be taken when comparing results obtained with different types of human cells (also see refs [26] [27] [28] .
The mutagenesis data discussed above apparently differ from those reported by Domoradzki and co-workers (4,15) for human cells exposed to MNNG. In latter studies the dose-response curves for both cell killing and 6TG-resistant mutants obtained in fibroblast strains displaying high levels of MGMT activity contained a non-effective region at low MNNG doses (i.e. ^ 2 fiM), followed by an exponential region at higher doses. The critical DNA defect responsible for both lethality and mutagenesis caused by MNNG was proposed to be O 6 meG since, unlike that seen for other alkylation products, the repair rate of this lesion decreased drastically with increasing mutagen dose (35) . Further studies are thus necessary to investigate the basis for the observations that in non-transformed, MGMT-proficient human fibroblast strains the relationship between the frequency of 6TG-resistant mutants and carcinogen dose is linear for MNU (40; this study) and biphasic for MNNG (4, 15) .
In summary, our results show that in the two human fetal fibroblast strains GM10 and GM11 the level of cellular MGMT activity correlates with the sensitivity to MNU-induced loss of colony-forming ability but not with the induction of 6TG-resistant mutants by this agent. The susceptibility of GM10 (MGMTproficient) cells to the mutagenic action of MNU was ~ 5 times greater than that reported by others for non-fetal normal human fibroblast strains (40) . It remains to be elucidated whether this hypersensitive response is peculiar to GM10 cells or is characteristic of MGMT-proficient strains of human fetal origin in general.
